Skip to main content
. Author manuscript; available in PMC: 2023 Apr 19.
Published in final edited form as: Circulation. 2022 Apr 18;145(16):1234–1237. doi: 10.1161/CIRCULATIONAHA.122.059278

Figure.

Figure

The role of lncExACT1 in physiological and pathological cardiac hypertrophy.

Left. LncRNA screening identified lncExACT1 downregulation during exercise (wheel-running) of mice that was associated with physiological cardiac hypertrophy. Mimicking exercise-induced lncExACT1 downregulation by systemic injection of antisense locked nucleic acid (LNA)-GapmeR-lncExACT1 protected against the development of heart failure in 2 disease models. Right. lncExACT1 expression was upregulated in hearts of mice in response to thoracic aortic constriction (TAC) and in human heart failure patients with non-ischemic cardiomyopathy. Adeno-associated virus (AAV)-mediated overexpression of lncExACT1 in mouse hearts induced cardiac dysfunction and pathological cardiac hypertrophy. (Figure created with BioRender.com)